Search Results - "KIRBY, A. M"

Living with invisible illness: social support experiences of individuals with systemic lupus erythematosus by Brennan, Kirby A. M., Creaven, Ann-Marie

“…Purpose Because symptoms are not immediately visible to others, systemic lupus erythematosus (SLE) is often considered an invisible illness. This invisibility…”
Get full text

Intraoperative radiotherapy in early stage breast cancer: potential indications and evidence to date by Hanna, G G, Kirby, A M

“…Following early results of recent studies of intraoperative radiotherapy (IORT) in the adjuvant treatment of patients with early breast cancer, the clinical…”
Get full text

Gefitinib (ZD1839, Iressa™) as palliative treatment in recurrent or metastatic head and neck cancer by KIRBY, A. M, A'HERN, R. P, D'AMBROSIO, C, TANAY, M, SYRIGOS, K. N, ROGERS, S. J, BOX, C, ECCLES, S. A, NUTTING, C. M, HARRINGTON, K. L

“…To assess the level of activity and toxicity of gefitinib (ZD1839, Iressatrade mark) in a population of patients with locally recurrent and/or metastatic head…”
Get full text

Cardiac Side-effects From Breast Cancer Radiotherapy by Taylor, C.W, Kirby, A.M

“…Abstract Breast cancer radiotherapy reduces the risk of cancer recurrence and death. However, it usually involves some radiation exposure of the heart and…”
Get full text

How Low Can You Go? The Radiobiology of Hypofractionation by Brand, D.H., Kirby, A.M., Yarnold, J.R., Somaiah, N.

“…Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being…”
Get full text

The role of the radiation therapy breast boost in the 2020s by Dzhugashvili, M., Veldeman, L., Kirby, A.M.

“…Given that most local relapses of breast cancer occur proximal to the original location of the primary, the delivery of additional radiation dose to breast…”
Get full text

Locoregional control and toxicity following high-dose hypofractionated and accelerated palliative radiotherapy regimens in breast cancer by Webb, K., Gothard, L., Mohammed, K., Kirby, A.M., Locke, I., Somaiah, N.

“…For patients with locally advanced primary/recurrent breast cancer, radiotherapy is an effective treatment for locoregional control. 36 Gy in 6 Gy once-weekly…”
Get full text

Ten-Year Outcomes of Stereotactic Body Radiotherapy for Oligometastatic Breast Cancer: Does Synchronous Oligometastatic Breast Cancer Benefit? by Nagpal, S.K., Khabra, K., Ross, G., Kirby, A.M.

“…The benefit of stereotactic body radiotherapy (SBRT) in metachronous oligometastatic breast cancer (OMBC) has previously been described and its use in current…”
Get full text

Five-fraction Radiotherapy for Breast Cancer: FAST-Forward to Implementation by Brunt, A.M., Haviland, J.S., Kirby, A.M., Somaiah, N., Wheatley, D.A., Bliss, J.M., Yarnold, J.R.

“…The phase 3 FAST-Forward trial reported outcomes for 26 and 27 Gy schedules delivered in 5 fractions over 1 week versus 40 Gy in 15 fractions over 3 weeks in…”
Get full text

European Society of Radiotherapy and Oncology (ESTRO) strategy 2024–2026: Growth and diversification in a rapidly changing world by Kirby, A.M., Guckenberger, M., Slotman, B.J., Clark, C.H., Eriksen, J.G., van der Heide, U., De Ioanna, S., Gasparotto, C., Cortese, A.J., Aznar, Marianne, Borgmann, Kerstin, Forde, Elizabeth, Jornet, Nuria, Meattini, Icro, Tanderup, Kari, Troost, Esther, Verellen, Dirk

“…•ESTRO members value access to high-quality scientific content alongside networking opportunities.•A 2023–4 ESTRO strategy review re-evaluated strategic…”
Get full text

Three-dimensional simulation of aesthetic outcome from breast-conserving surgery compared with viewing photographs or standard care: randomized clinical trial by Godden, A R, Micha, A, Wolf, L M, Pitches, C, Barry, P A, Khan, A A, Krupa, K D C, Kirby, A M, Rusby, J E

“…Over half of women with surgically managed breast cancer in the UK undergo breast-conserving treatment (BCT). While photographs are shown prior to…”
Get full text

From 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy by Yarnold, J.R., Brunt, A.M., Chatterjee, S., Somaiah, N., Kirby, A.M.

“…There is a sound empirical basis for hypofractionation in radiotherapy for breast cancer. This article reviews the radiobiological implications of…”
Get full text

Hitting the Target: Developing High-quality Evidence for Proton Beam Therapy Through Randomised Controlled Trials by Hudson, E M, Slevin, F, Biscombe, K, Brown, S R, Haviland, J S, Murray, L, Kirby, A M, Thomson, D J, Sebag-Montefiore, D, Hall, E

“…The National Health Service strategy for the delivery of proton beam therapy (PBT) in the UK provides a unique opportunity to deliver high-quality evidence for…”
Get full text

A Randomised Phase II Clinical Trial Comparing the Deliverability and Acute Toxicity of Wide Tangent versus Volumetric Modulated Arc Therapy to the Breast and Internal Mammary Chain by Ranger, A, Dunlop, A, Hansen, V N, Princewill, G, Landeg, S, Donovan, E M, Harris, E J, McNair, H A, Haviland, J, Kirby, A M

“…Inclusion of the internal mammary chain in the radiotherapy target volume (IMC-RT) improves disease-free and overall survival in higher risk breast cancer…”
Get full text

Challenges in the treatment of breast cancer brain metastases: evidence, unresolved questions, and a practical algorithm by Meattini, I., Andratschke, N., Kirby, A. M., Sviri, G., Offersen, B. V., Poortmans, P., Kaidar Person, O.

“…Breast cancer is the leading cause of brain metastases in women. Large randomized clinical trials that have evaluated local therapies in patients with brain…”
Get full text

Proton Beam Therapy in Breast Cancer Patients: The UK PARABLE Trial is Recruiting by Kirby, A.M., Haviland, J.S., Mackenzie, M., Fleming, H., Anandadas, C., Wickers, S., Miles, E., Iles, N., Bliss, J.M., Coles, C.E., Taylor, C., Kirwan, C., Lines, D., Provenzano, E., Gleeson, I., Bhattacharya, I., Wolstenholme, J., Aznar, M., Merchant, M., Howe, P., Butt, R., Gulliford, S., Settatree, S., McMahon, S., Richards, T., Tsang, Y., Cafferty, F., Toms, C., Redman, E., Biscombe, K.

Get full text

The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy by Bartlett, F.R, Donovan, E.M, McNair, H.A, Corsini, L.A, Colgan, R.M, Evans, P.M, Maynard, L, Griffin, C, Haviland, J.S, Yarnold, J.R, Kirby, A.M

“…Abstract Aims To evaluate the feasibility and heart-sparing ability of the voluntary breath-hold (VBH) technique in a multicentre setting. Materials and…”
Get full text

A review of permanent marking for radiotherapy in the UK by Townend, C., Landeg, S., Thorne, R., Kirby, A.M., McNair, H.A.

“…This paper presents the results of a survey of the routine use of permanent marks for radiotherapy in the UK. This was undertaken to provide an overview of…”
Get full text

The IMPORT LOW Trial: Collaborative Research Accelerates Practice Change in Breast Radiotherapy by Kirby, A.M., Bhattacharya, I.S., Wilcox, M., Haviland, J.S.

Get full text

Can Interrogation of Tumour Characteristics Lead us to Safely Omit Adjuvant Radiotherapy in Patients with Early Breast Cancer? by Bhattacharya, I.S., Kirby, A.M., Bliss, J.M., Coles, C.E.

“…Adjuvant radiotherapy after breast-conserving surgery has been an important component of the standard of care for early breast cancer. Improvements in breast…”
Get full text